Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Admilparant and Pirfenidone in Healthy Participants
NCT03981094Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of admilparant in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration, Area under the serum concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started May 2019; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03981094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981094.